Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Market Reports
Chemistry meets biology: an integrated approach to developing and manufacturing medicines of the future
Until recently, chemists and biologists rarely needed to collaborate to develop a new large molecule drug, reports Chris Conway, President, Research and Development, Curia
Closing the gap between biotherapies and their quality control
NGS-based biosafety tests are giving the biomanufacturing industry a facelift
Droplet microfluidics: leveraging the untapped potential of single-cell research and high-throughput screening
The age of personalised medicine requires modern tools. Recent research breakthroughs such as the meteoric rise of CRISPR technology and the emergence of single-cell sequencing have clearly shown a vast untapped potential in the life sciences, reports Juozas Nainys, CEO of Droplet Genomics
A smart approach to ready-to-use drug containment solutions
At a time when global healthcare providers are coming under previously unknown levels of pressure, their suppliers need to react with greater speed and flexibility to meet demand without compromising patient safety
Influence of material and capsule filling process on DPI aerosolisation performance
The effect of capsule filling parameters on emitted dose and fine particle fraction by a DPI was investigated using a benchtop capsule filling device. Compression was the parameter that affected weight and emitted fraction the most, whereas the type of coarse lactose seems to influence the fine particle fraction
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a still-unsaturated market. Dr Kevin Robinson spoke with the country’s Minister for Economy and Innovation, Aušrinė Armonaitė, to find out more
Driving biotherapeutic development with advanced molecule characterisation
Evaluating and characterising complicated protein structures and the therapeutic activity of advanced biotherapeutic molecules requires sensitive analytical technologies and informatics systems. As such, executing accurate, analytical assessments of complex biological molecules in a commercial laboratory setting can be challenging, explains Eliza Lee, Lead Scientist Analytics, Samsung Biologics
Deciding on a chemistry, manufacturing and control strategy for biologic development
Khanh Ngo Courtney from Avomeen discusses what biopharmaceutical companies should keep in mind as they embark on their CMC journey
The new regulatory world for medical devices
Establishing an effective compliance strategy now ahead of the 2022 IVDR legislation is critical — because there’s more to come
Manufacturing vaccines, digital twins and lessons learned: part I
Using a digital replica of the manufacturing process, the pharmaceutical industry is exploring the ability of virtual technology to improve the efficiency and agility of the production chain and expedite time-to-market
Using ddPCR to accurately quantify AAV viral titre and integrity
Gene therapy is primed to become the next major development in medicine and bring relief to patients living with diseases ranging from haemophilia to Alzheimer’s disease, write Mark White, Associate Director of Biopharma Product Marketing, and Marwan Alsarraj, Biopharma Segment Manager, Bio-Rad
Opportunities to scale AAV viral vector production for gene therapies
Gene therapies hold tremendous potential as a treatment modality for inherited human diseases. This emerging therapeutic approach can correct or replace pathologic mutations, inactivate mutated genes that are functioning improperly and also introduce new genes to help our bodies fight diseases. Thermo Fisher Scientific's Mike Brewer and Alejandro Becerra report
Big names confirmed to speak at Manufacturing Chemist Live
NASA and AstraZeneca have joined the extensive list of speakers for the combined virtual and in-person event
Refining test methods for a new generation of nasal drug products
The nasal drug product market is currently the focus of considerable research activity. Nasal sprays for local action, such as the treatment of illnesses including allergic rhinitis and hay fever, dominate in terms of market volume and are an important target for generic manufacturers, report Anna Sipitanou, Business Development Manager, and Mark Copley, CEO, Copley Scientific
Taking a holistic approach to quality management
Ensuring quality is one of the most important tasks for bio/pharmaceutical innovators and their external partners. This is vital to keep patients safe and healthy, as well as avoid unnecessary regulatory delays during the development process
Real world evidence: helping to end COVID-19 disruption
Truly bringing the COVID-19 pandemic under control will take concerted efforts beyond the rollout of a global mass vaccination programme. Understanding the real-world performance of vaccines and treatments has a key part to play to identify how and when improvements can be made to enhance their effectiveness in the future
Manufacturing Chemist Live: A hybrid event
Taking place on 14-15 September, the event will put delegates ahead of the curve in the global pharmaceutical supply chain
Pure, smooth and strong
The EVERIC range of pharmaceutical vials from SCHOTT meets the challenges of today’s fill and finish lines
Pharmaceutical reshoring: a healthy requirement, a strategic necessity
More than a year into the COVID-19 crisis, the novel coronavirus continues to disrupt our societies, including how the pharmaceutical industry operates; Andrew Badrot, CEO of C<sup>2</sup> PHARMA, discusses the ongoing ramifications of the pandemic
Taking a lifecycle approach to fill-finish success
Dr Kevin Robinson recently spoke to swissfillon founder and CEO, Daniel Kehl, and Business Development Director, Carole Delauney, to discuss the company’s baptism by fire during the COVID-19 pandemic and how they can help companies succeed in the pharmaceutical industry’s “new normal”
Lessons learned from the COVID-19 pandemic
As vaccines roll out and COVID-19 cases begin to decline, Amélie Boulais, Head of Market Entry Strategy for Virus Based Therapeutics at Sartorius, reflects on key takeaways that will impact the biopharmaceutical industry’s approach to pandemic preparedness in 2021 and beyond
Harnessing the power of HPAPIs: key considerations
Adam Kujath, Senior Director at Sterling Pharma Solutions, discusses the key issues that companies need to consider when embarking on an HPAPI project. He also outlines what can go wrong if the right steps are not taken to ensure effective containment and gives insight into how access to the right expertise can help to accelerate timelines
From dark art to an age of enlightenment
Much is happening in the realms of Almac’s GMP peptides business in terms of growth, development and strategic operations. And, with the company’s current focus on neoantigen-derived vaccines that harness the body’s own immune system to fight cancer, Dr Kevin Robinson zoomed in to find out more
The application of picodroplet technology for biopharmaceutical discovery and scientific research
Picodroplet technologies continue to push the boundaries of biologic discovery by accelerating research, expanding the scope of exploration and reducing drug discovery and development costs, explains Olivia Hughes, Senior Marketing Associate at Sphere Fluidics
Previous
1
2
(current)
3
4
5
6
7
8
9
Next
Trending Articles
Drug dose delivery development, manufacturing and commercialisation trends: part II
In the wake of patient-centricity in the pharmaceutical industry, drug delivery technologies have emerged as a central driver of therapeutic and patient success. Dr Kevin Robinson went online with Manuel Leal, Business Development Director, Idifarma, Steve Rode, Manager Business Development, Capsules and Health Ingredients, Lonza, and John Ross, President, Mayne Pharma US/Metrics Contract Services, to find out more
How to avoid sticking and picking in the tableting industry
John Norman and Kevin Queensen of Natoli Engineering explain
Adding more to the cell and gene therapy playbook
With notable advances in various forms of administration, including making the use of viral vectors safer, non-viral delivery with lipid nanoparticles and the growing application of electroporation, Dr Kevin Robinson (KSR) recently caught up with Jason Potter (JP), Director of Cell Biology R&D at Thermo Fisher Scientific, to learn more about how the company is helping the pharmaceutical industry to develop cell and gene therapies
How to proactively address EU HTAR implementation challenges before 2025
Data landscape challenges within the European Union (EU) have historically been driven by the different laws, processes and regulatory standards of its 27 member states (MS). As a result, drug therapeutics and health technology developers have faced the challenge of duplication of assessment efforts
Highly potent formulation development in oncology
Formulation development is a dynamic and experimental process. However, certain challenges are presented to CDMOs that add a layer of unnecessary pressure to the development process — some of which are avoidable. Louise Carpenter from PCI Pharma Services discusses
Upcoming event
BIO International Convention Digital
3-6 June, 2024 | Convention | San Diego, US
See all